Clinical Trials
3 trialsNCT05618613 2025-05-09
ELONA
Context Therapeutics Inc.
Phase 1/2 Terminated
NCT06938711 2025-04-22
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Context Therapeutics Inc.
Phase 1/2 Withdrawn
NCT02052128 2015-06-24
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Arno Therapeutics
Phase 1/2 Unknown